C2 PHARMA STRENGTHENS OPHTHALMIC API PORTFOLIO WITH TIMOLOL MALEATE LAUNCH
Cork, Ireland, October 13th, 2025– C2 PHARMA, the global leader in ophthalmic APIs announces the launch of its latest API, Timolol Maleate. The validation campaign for Timolol Maleate was completed in August 2025, and a Certificate of Suitability (CEP) was filed on 10 October 2025. The US-Drug Master File (US-DMF) is planned for submission in December 2025.
Timolol Maleate is a beta-blocker widely used in ophthalmology for the treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma. It is a cornerstone API in eye care.
To reinforce supply security and accelerate market access, C2 PHARMA has transferred the production of Timolol Maleate to one of its trusted contract manufacturing partners SMS Lifesciences.
“C2 PHARMA is committed to provide the most reliable, sustainable, and cost-effective supply of high-quality ophthalmic APIs to the global pharmaceutical market, with more strategic launches planned in the near future, as well as the upcoming release of Dorzolamide and Brinzolamide ” states Andrew Badrot, CEO of C2 PHARMA.
Meet the C2 PHARMA team at CPhI Worldwide in Frankfurt, October 28–30, 2025 (booth 11.0C14) or contact info@c2pharma.com to schedule a meeting.
About C2 PHARMA
C2 PHARMA is the global leader in ophthalmic active pharmaceutical ingredients (APIs). Founded in 2014 and headquartered in Cork, Ireland, C2 PHARMA ensures a consistent supply of high-quality APIs at competitive prices, serving over 200 pharmaceutical companies worldwide. Their specialized affiliate, Logistics4Pharma (Frankfurt, Germany), provides tailored GDP-compliant cold-chain logistics solutions.
Media Contact
Serge Tarabay